Rubedo Life Sciences is an anti-aging company which aims to develop medicine that targets the drivers of aging. They are looking to eliminate specific cells that enables the aging process and create disease. As such they look to extend human health span by restoring biological youth at a cellular level.
They have the following mission statement:
Rubedo discovers and develops medicines to keep you biologically young by targeting the pathologic cells that drive aging
Feel welcome to share your own thoughts on this company in the comment section below as well. I will be happy to discuss and learn more about how you see their potential in this field.
The Solution
Rubedo Life Sciences has developed a proprietary drug discovery platform named Alembic. Through this they identify novel targets by leveraging single cell RNA sequencing to identify pathologic senescent cells that are unique to age-related diseases. Specifically pathologic cells that play a key role in the progression of pulmonary, dermatological, oncological, neurodegenerative, fibrotic and other chronic disorders.
To elaborate a bit then senescence cells are cells that have aged to a point where they no longer divide, but also do not die. An accumulation of these cells can reach a critical mass at which point they can cause chronic inflammation and damage leading to fibrosis and tissue degeneration. This process drives many age-related diseases, including various types of cancer.
You can view their official pipeline in the below image from their website:
The lead candidate from their pipeline is RLS-1496, which targets chronic atopic dermatitis and chronic psoriasis. RLS-1496 is currently at the IND-enabling phase, which is basically toxicology studies conducted prior to human studies. The next step from here has also been confirmed to be a phase 1 clinical trial, which is expected to take place in Q1 of 2025.
With this list of programs with potential candidates it is exciting to follow the progress. Although, they do not disclose any information on the other candidates. If the Alembic platform is proven effective at selecting the optimal targets for therapeutic intervention then it seems as though there is a lot of potential in this pipeline.
The company
Rubedo Life Sciences was founded in 2018, and is headquartered in Silicon Valley, CA, USA. The company was founded by Marco Quarta, Mark Gallop, and Julian Klein.
Their most recent funding was raised in April 2024 from a series A round. Through this round they secured $40M, which was led by Khosla Ventures and Ahren Innovation Capital. This series A funding round was held in order to finance the phase 1 clinical trial for their lead pipeline candidate RLS-1496. It will be exciting to follow the development here and see how their first clinical trial in this field performs.
Read about more anti-aging companies on this website through this link.
